Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

GLAM role for Callaghan Innovation customer Dexibit

GLAM role for Callaghan Innovation customer Dexibit

Callaghan Innovation has applauded the success of one of its customers, Dexibit, which today announced a collaboration with London’s National Gallery.

Dexibit has developed a product for galleries, libraries, archives and museums – known collectively as the GLAM sector –to better understand visitor experience. Callaghan Innovation has supported development of the product, which uses Big Data analytics and Artificial Intelligence (AI) techniques such as machine learning, since early 2016.

The collaboration with the National Gallery is a great accolade for Dexibit, Callaghan Innovation spokesman Hēmi Rolleston says.

“It reflects the value of investing in innovators, which is what we are here to do,” Mr Rolleston, General Manager Sectors, says. “We’re here to connect businesses to the networks, capability and funding they need to make their ideas happen.”

Using predictive analytics the Dexibit product considers a range of variables such as the weather, school terms and visitor movements to provide GLAM institutions with deeper insights into visitor experience, and future exhibition scenarios. This can help with recruiting visitors and funding.

Callaghan Innovation support was provided through Auckland’s economic development agency, Auckland Tourism, Events and Economic Development (ATEED), which is one of fourteen organisations across New Zealand contracted to deliver the government’s Regional Business Partner programme. As well as providing access to Callaghan Innovation services, Regional Business Partners connect companies to business capability funding, business mentors, expertise, connections and local business initiatives.

Dexibit CEO Angie Judge says the support from Callaghan Innovation helped them make the leap from big data analytics to machine learning.

“Callaghan Innovation has done such a wonderful job of sharing our vision for the future with intelligent insights for visitor behaviour, and supporting us in rapidly and meaningfully bringing innovative advancements to the cultural sector.”

Mr Rolleston said Dexibit’s success exemplifies the value of Callaghan Innovation’s approach.

“Congratulations to Dexibit, who in relatively short time have found international success. Stepping up to the challenge of technological change is something New Zealand has to do if we are to compete successfully in today’s world.”


ENDS


© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Marine And Freshwater Reports: EDS Calls For Urgent Action On Marine Management

“There are some big issues to address. These include many marine species and habitats that are in serious trouble. Of the sample investigated, the report finds that 22% of marine mammals, 90% of seabirds and 80% of shorebirds are threatened with or actually at risk of extinction..." More>>

ALSO:

$7.5 Billion Surplus: Government Accounts "Show Strong Economy"

“The surplus and low levels of debt show the economy is in good shape. This allows the Government to spend more on infrastructure and make record investments in health and education,” Grant Robertson says. More>>

ALSO:

New OIO Application Trumps Judicial Review: OceanaGold Cleared To Buy Land For Waihi Tailings Expansion

In a surprise turnaround, the government has given OceanaGold a greenlight to buy land to expand its Waihi mine after the application was previously turned down by Land Information Minister Eugenie Sage. More>>

ALSO:

Christchurch Rebuild: Fletcher Sued For $7.5m Over Justice Precinct

Fletcher Building is being sued for $7.5 million by utilities contractor Electrix, one of the subcontractors on the Christchurch Justice and Emergency Services Precinct. More>>

Three New Drugs: PHARMAC Signs Bundle Deal For More Cancer Medicines

420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier. More>>

ALSO: